Detalhe da pesquisa
1.
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Br J Haematol
; 204(5): 1825-1829, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38286472
2.
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Anticancer Drugs
; 35(1): 63-69, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37067996
3.
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.
Hematol Oncol
; 40(4): 695-703, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488778
4.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
J Natl Compr Canc Netw
; 20(6): 622-634, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714675
5.
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Ann Hematol
; 100(1): 143-155, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32488603
6.
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.
Am J Hematol
; 96(8): 945-953, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909933
7.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(2): 185-217, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32023533
8.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
Blood
; 130(10): 1198-1204, 2017 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28684537
9.
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Blood
; 129(26): 3419-3427, 2017 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28424162
10.
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.
J Natl Compr Canc Netw
; 17(1): 12-20, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30659125
11.
IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.
Am J Hematol
; 94(3): 338-345, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30575108
12.
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Br J Haematol
; 183(2): 196-211, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30080238
13.
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.
Br J Haematol
; 183(3): 421-427, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30117139
14.
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Blood
; 127(22): 2693-700, 2016 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27009059
15.
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Haematologica
; 103(12): 2079-2087, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30237264
16.
Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies.
Ann Hematol
; 97(3): 519-528, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29218388
17.
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Blood
; 126(11): 1294-301, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26157076
18.
Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.
Am J Hematol
; 92(12): 1362-1369, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28940587
19.
Ixazomib and lenalidomide maintenance therapy in multiple myeloma.
Ann Hematol
; 100(3): 851-853, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33161454
20.
Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.
Cancer
; 121(17): 2883-91, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25931291